Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lionel Hebbard

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Oncotarget|February 11, 2016
Aptamers: A promising chemical antibody for cancer therapyGang Zhou, George Wilson, Lionel Hebbard, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 29, 2014
Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in ratsKaren L Thomsen, Lionel Hebbard, Emilie Glavind, et al.
Cancer Letters|August 15, 2013
Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitroGeorge S Wilson, Aiping Tian, Lionel Hebbard, et al.
World Journal of Gastroenterology|December 4, 2014
Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma developmentChun-Meng Jiang, Chun-Wen Pu, Ya-Hui Hou, et al.
Molecular Cancer|October 25, 2017
Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cellsXiaoqi Huo, Shuanglin Han, Guang Wu, et al.
Theranostics|November 8, 2017
Aptamer-Based Therapeutic Approaches to Target Cancer Stem CellsGang Zhou, Olivier Latchoumanin, Mary Bagdesar, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|June 14, 2014
Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic functionKaren Louise Thomsen, Henning Grønbæk, Emilie Glavind, et al.
Scientific Reports|October 8, 2020
The effects of fructose and metabolic inhibition on hepatocellular carcinomaBrittany Dewdney, Mohammed Alanazy, Rhys Gillman, et al.
Molecular Cancer Therapeutics|March 22, 2014
Embelin reduces colitis-associated tumorigenesis through limiting IL-6/STAT3 signalingYun Dai, Hongmei Jiao, Guigen Teng, et al.
Cancer Letters|July 1, 2014
Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cellsAiping Tian, George S Wilson, Stefanus Lie, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Oncotarget|February 11, 2016
Aptamers: A promising chemical antibody for cancer therapyGang Zhou, George Wilson, Lionel Hebbard, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 29, 2014
Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in ratsKaren L Thomsen, Lionel Hebbard, Emilie Glavind, et al.
Cancer Letters|August 15, 2013
Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitroGeorge S Wilson, Aiping Tian, Lionel Hebbard, et al.
World Journal of Gastroenterology|December 4, 2014
Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma developmentChun-Meng Jiang, Chun-Wen Pu, Ya-Hui Hou, et al.
Molecular Cancer|October 25, 2017
Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cellsXiaoqi Huo, Shuanglin Han, Guang Wu, et al.
Theranostics|November 8, 2017
Aptamer-Based Therapeutic Approaches to Target Cancer Stem CellsGang Zhou, Olivier Latchoumanin, Mary Bagdesar, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|June 14, 2014
Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic functionKaren Louise Thomsen, Henning Grønbæk, Emilie Glavind, et al.
Scientific Reports|October 8, 2020
The effects of fructose and metabolic inhibition on hepatocellular carcinomaBrittany Dewdney, Mohammed Alanazy, Rhys Gillman, et al.
Molecular Cancer Therapeutics|March 22, 2014
Embelin reduces colitis-associated tumorigenesis through limiting IL-6/STAT3 signalingYun Dai, Hongmei Jiao, Guigen Teng, et al.
Cancer Letters|July 1, 2014
Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cellsAiping Tian, George S Wilson, Stefanus Lie, et al.
Pageof 5